On November 15, 2022, Casma Therapeutics, Inc. closed the transaction. The received $46 million in Series C round of funding. The transaction included participation from new investors Amgen Ventures, Astellas Venture Management LLC, Eisai Co., Ltd., Euclidean Capital LLC, Mirae Asset Global Investments (India) Pvt.

Ltd and Ono Venture Investment, Inc., and returning investors Schroders Capital, Eventide Asset Management, LLC, The Column Group LLC, and Third Rock Ventures, LLC and other funds. As part of the transaction, Hiromichi Kimura of Astellas Ventures, has joined the board of directors. Tomotaka Okino of Ono Venture Investment and Amgen Ventures have joined as board observers.

The company issued 100,000,000 shares.